DB
TVRD

Dmitry Balyasny’s Tvardi Therapeutics TVRD Stock Holding History

Dmitry Balyasny’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,278
Closed -$3.49M – 1810
2017
Q1 		$3.49M Buy
+5,278
New +$2.82M 0.02% 778

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dmitry Balyasny's TVRD Position: Q4 2022 in Review

Dmitry Balyasny sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 541 shares — an estimated $182K sold.

Dmitry Balyasny first reported a position in TVRD in Q1 2016 and held it in 9 quarters. The position peaked at $8.08M in Q2 2017. 160 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

  • Dmitry Balyasny reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 541 Tvardi Therapeutics shares in Q4 2022, an estimated $182K.
  • Dmitry Balyasny first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 9 quarters.
  • Dmitry Balyasny's Tvardi Therapeutics position peaked at $8.08M in Q2 2017.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.